Effect of Ciprofibrate on Platelet Aggregation and Fibrinolysis in Patients with Hypercholesterolaemia

Iain A Simpson; A Ross Lorimer; Isobel D Walker; John F Davidson

doi:10.1055/s-0038-1657868

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1985; 54(02): 442-444
DOI: 10.1055/s-0038-1657868

Original Article

Schattauer GmbH Stuttgart

Effect of Ciprofibrate on Platelet Aggregation and Fibrinolysis in Patients with Hypercholesterolaemia

Autor*innen

Iain A Simpson

The University Department of Medical Cardiology and Department of Haematology, Royal Infirmary, Glasgow, UK
A Ross Lorimer

The University Department of Medical Cardiology and Department of Haematology, Royal Infirmary, Glasgow, UK
Isobel D Walker

The University Department of Medical Cardiology and Department of Haematology, Royal Infirmary, Glasgow, UK
John F Davidson

The University Department of Medical Cardiology and Department of Haematology, Royal Infirmary, Glasgow, UK

Abstract

als PDF herunterladen

Summary

The fibrinolytic and platelet effects of Ciprofibrate, a new lipid lowering drug, were studied in 7 patients with hypercholesterolaemia over a 12 week period. A significant reduction in plasma fibrinogen was noted and a lesser increase in fibrinolytic activity. However, no change in platelet aggregation was noted. As expected Ciprofibrate produced a significant hypolipidaemic effect in these patients.

We have described effects of Ciprofibrate which may have potential benefits in this high risk patient group.

Keywords

Ciprofibrate - Hypolipidaemic agent - Fibrinolytic activity - Fibrinogen - Hypercholesterolaemia

PDF (451 kb)

Referenzen

References
1 Arnold A, McAuliff JP, Powers LG, Phillips DK, Beyler AL. The results of animal studies with Ciprofibrate, a new orally effective hypolipidaemic drug. Atherosclerosis 1979; 32: 155-163
2 Illingworth DR, Olsen GD, Cook SF, Sexton GJ, Wendel HA. Ciprofibrate in the Therapy of Type II Hypercholesterolaemia. A double-blind trial. Atherosclerosis 1982; 44: 211-221
3 Calvert GD, Blight L, Franklin J, Oliver J, Wise P, Gallus AS. The effect of Clofibrate on plasma glucose, lipoproteins, fibrinogen and other biochemical and haematological variables in patients with maturity onset diabetes mellitus. Eur J Clin Pharmacol 1980; 17: 355-362
4 Chakrabarti R, Fearnley GR. Effect of Clofibrate on fibrinolysis, platelet stickiness, plasma fibrinogen and serum cholesterol. Lancet 1968; 2: 1007-1009
5 Cotton RC, Wade EG, Spiller GW. The effect of Atromid on plasma fibrinogen and heparin resistance. J Atheroscler Res 1963; 3: 648-652
6 Lipid Research Clinic Programme. Manual of Laboratory Operations. DHEW Publication No 1975 (NIH). 75-268
7 Kluft C, Brakman P, Veldhuyzen-Stolk EC. Screening of fibrinolytic activity in plasma euglobulin fractions on the fibrin plate. In: Progress in Chemical Fibrinolysis and Thrombolysis. Davidson JF, Samama MM, Desnoyers PC. (eds) Vol 2 57-65 Raven Press; New York: -1976
8 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
9 Friberger P, Knos M. Plasminogen assay in human plasma. In: Chromogenic Peptide Substrates (Chemistry and Clinical Usage). Scully MF, Kakkar VV. (eds) 128-140 Churchill Livingstone, Edinburgh: 1979
10 Davignon J, Gascon B, Brossard D, Quidoz S, Leboeuf N, Le Lorier J. In: Lipoproteins and Coronary Atherosclerosis. Noseda G, Frogiacomo C, Fumagalli R, Paoletti R. (eds) 213-221 Elsevier Biomedical Press B. V.; Amsterdam: 1982
11 Olsson AG, Oro L. Dose response study of the effect of Ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. Atherosclerosis 1982; 42: 229-243
12 Lowe GDO, Drummond MM, Third JLHC, Bremner WF, Forbes CD, Prentice CRM, Lawrie TDV. Increased plasma fibrinogen and platelet aggregates in type II hyperlipoproteinaemia. Thromb Haemostas 1980; 42: 1503-1507
13 McDonald L, Edgill M. Coagulability of the blood in ischaemic heart disease. Lancet 1975; 2: 457-463
14 Baker IA, Eastham R, Elwood PC, Etherington M, O'Brien JR, Sweetnam PM. Haemostatic factors associated with ischaemic heart disease in men aged 45 to 64 years. The Speedwell Study. Br Heart J 1982; 47: 490-494
15 Meade TW, North WR, Chakrabarti R, Haines AP, North WRS, Stirling Yvonne, Thomson SG, Brozovic M. Haemostatic function and cardiovascular death: Early results of a prospective study. Lancet 1980; 1: 1050-1054
16 Research Committee of the Scottish Society of Physicians. Ischaemic Heart Disease: A secondary prevention trial using Clofibrate. Br Med J 1971; 4: 775-784
17 Physicians of the Newcastle upon Tyne Region. Trial of Clofibrate in the treatment of ischaemic heart disease. Br Med J 1971; 4: 767-774
18 Coronary Drug Project Research Group. JAMA. 1975; 231: 360-381
19 Verheijen JH, Rijken DC, Chang GTG, Preston F, Kluft C. Decreased levels of rapid tissue-type plasminogen activator inhibitor by oral administration of Stanozalol. In: Progress in Fibrinolysis VII. Davidson JF, Donati MB, Coccheri SF. (eds) Churchill Livingstone, Edinburgh: 1985
20 Whitaker KB, Costa D, Moss DW. Selective effects of Clofibrate on alkaline phosphatase coenzymes in serum. Clin Chim Acta 1979; 94: 191-196
21 Panchenko LF, Popova SV, Antonenkov VD. Inducing effect of Clofibrate on alkaline phosphatase and histidine ghyoxylate amino-transferase in rat liver. Experientia 1982; 38: 433-434